{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T04:26:53Z","timestamp":1786249613957,"version":"build-2736575974"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the association of plasma aldosterone concentration (PAC) with incident cardiovascular disease (CVD) and all-cause mortality in hypertensive patients with suspected obstructive sleep apnea (OSA) and calculate the optimal cut-off value of PAC for this specific population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>Participants with PAC at baseline in UROSAH in 2011-2013 were enrolled and followed up till 2021. Composite outcome included CVD and all-cause mortality. Cox proportional hazards model was used to evaluate the relationship between PAC and the composite outcome. Time-dependent ROC curve was used to determine the optimal cut-off value of PAC. Besides, we conducted subgroup analyses and sensitivity analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>3173 hypertensive participants aged 18-84 years comprised analytical sample. During a median follow-up of 7.3 years and 22640 person-years, 69 deaths and 343 cases of incident CVD occurred. The incidence of composite outcome was increased with elevation in tertile of PAC. Compared with the first tertile, the risk of CVD and all-cause death was higher in third tertile (HR=1.81, 95%CI: 1.39-2.35, P&amp;lt;0.001). Time-dependent ROC curve showed optimal threshold for PAC was 12.5ng\/dl. Whether renin was suppressed or not (\u22640.5 or &amp;gt;0.5ng\/ml per h), elevated PAC was associated with an increased risk of CVD. Our results remained stable and consistent in sensitivity analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Higher PAC was associated with increased risk of CVD and all-cause mortality in hypertensives with suspected OSA, even in the absence of primary aldosteronism (PA). Hypertensives with PAC\u226512.5ng\/dl showed a significantly increased risk of CVD, indicating that special attention and treatment were required in this specific population.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.1017177","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T05:26:30Z","timestamp":1665120390000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Higher plasma aldosterone is associated with increased risk of cardiovascular events in hypertensive patients with suspected OSA: UROSAH data"],"prefix":"10.3389","volume":"13","author":[{"given":"Lin","family":"Gan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulalibieke","family":"Heizhati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyue","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junli","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1161\/CIRCRESAHA.117.308903","article-title":"Reducing the global burden of cardiovascular disease, part 1: The epidemiology and risk factors","volume":"121","author":"Joseph","year":"2017","journal-title":"Circ Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: Update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30427-1","article-title":"Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the global burden of disease study 2017","volume":"394","author":"Zhou","year":"2019","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2017.07.091","article-title":"Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies","volume":"94","author":"Patel","year":"2017","journal-title":"BioMed Pharmacother"},{"key":"B6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2010.30","article-title":"Aldosterone: effects on the kidney and cardiovascular system","volume":"6","author":"Briet","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.3390\/ijms23042111","article-title":"Parasiliti-Caprino M. atrial fibrillation and aortic ectasia as complications of primary aldosteronism: Focus on pathophysiological aspects","volume":"23","author":"Bollati","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-013-0330-y","article-title":"Aldosterone and the risk of hypertension","volume":"15","author":"Xanthakis","year":"2013","journal-title":"Curr Hypertens Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000231338.41548.fc","article-title":"Plasma aldosterone is independently associated with the metabolic syndrome","volume":"48","author":"Bochud","year":"2006","journal-title":"Hypertension"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.180521","article-title":"Plasma aldosterone levels and development of insulin resistance: prospective study in a general population","volume":"58","author":"Kumagai","year":"2011","journal-title":"Hypertension"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002505","article-title":"Aldosterone predicts cardiovascular, renal, and metabolic disease in the general community: A 4-year follow-up","volume":"4","author":"Buglioni","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15006","article-title":"Serum aldosterone concentration, blood pressure, and coronary artery calcium: The multi-ethnic study of atherosclerosis","volume":"76","author":"Inoue","year":"2020","journal-title":"Hypertension"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e32831286fd","article-title":"Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism","volume":"26","author":"Bernini","year":"2008","journal-title":"J Hypertens"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq019","article-title":"Plasma aldosterone levels are associated with increased cardiovascular mortality: the ludwigshafen risk and cardiovascular health (LURIC) study","volume":"31","author":"Tomaschitz","year":"2010","journal-title":"Eur Heart J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2017.05.012","article-title":"Aldosterone, renin, cardiovascular events, and all-cause mortality among African americans: The Jackson heart study","volume":"5","author":"Joseph","year":"2017","journal-title":"JACC Heart Fail"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013790","article-title":"Plasma aldosterone levels are not associated with cardiovascular events among patients with high-risk vascular disease: Insights from the ACCELERATE trial","volume":"8","author":"Kumar","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055373","article-title":"Multiple biomarkers for the prediction of first major cardiovascular events and death","volume":"355","author":"Wang","year":"2006","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/01.crd.0000148845.74124.c0","article-title":"Interactions of high salt intake and the response of the cardiovascular system to aldosterone","volume":"13","author":"Conlin","year":"2005","journal-title":"Cardiol Rev"},{"key":"B22","doi-asserted-by":"publisher","first-page":"100029","DOI":"10.1016\/j.ijchy.2020.100029","article-title":"The 2020 Italian society of arterial hypertension (SIIA) practical guidelines for the management of primary aldosteronism","volume":"5","author":"Rossi","year":"2020","journal-title":"Int J Cardiol Hypertens"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.116.303587","article-title":"Hypertension: renin-angiotensin-aldosterone system alterations","volume":"116","author":"Te Riet","year":"2015","journal-title":"Circ Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: Case detection, diagnosis, and treatment: An endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.88.5.2460","article-title":"Human blood pressure determination by sphygmomanometry","volume":"88","author":"Perloff","year":"1993","journal-title":"Circulation"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.10263","article-title":"Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: A multicenter study in Japan","volume":"71","author":"Ohno","year":"2018","journal-title":"Hypertension"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.12.013","article-title":"Aldosterone and long-term outcome after myocardial infarction: A substudy of the french nationwide observatoire sur la prise en charge hospitaliere, l'Evolution a un an et les caRacteristiques de patients presentant un infArctus du myocarde avec ou sans onde q (OPERA) study","volume":"157","author":"Beygui","year":"2009","journal-title":"Am Heart J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.19134","article-title":"Cardiac structure and function across the spectrum of aldosteronism: the atherosclerosis risk in communities study","volume":"79","author":"Brown","year":"2022","journal-title":"Hypertension"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1247545","article-title":"Reference intervals for aldosterone, renin, and the aldosterone-to-renin ratio in the population-based study of health in pomerania (SHIP-1)","volume":"42","author":"Hannemann","year":"2010","journal-title":"Horm Metab Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2011.47","article-title":"Resistant hypertension, obstructive sleep apnoea and aldosterone","volume":"26","author":"Dudenbostel","year":"2012","journal-title":"J Hum Hypertens"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.16902","article-title":"Prospective screening for primary aldosteronism in patients with suspected obstructive sleep apnea","volume":"77","author":"Chee","year":"2021","journal-title":"Hypertension"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.00613","article-title":"Obstructive sleep apnea and hypertension: an update","volume":"63","author":"Konecny","year":"2014","journal-title":"Hypertension"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30198-5","article-title":"Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis","volume":"7","author":"Benjafield","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: Detection, evaluation, and management: A scientific statement from the American heart association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1017177\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T05:26:35Z","timestamp":1665120395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.1017177\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":37,"alternative-id":["10.3389\/fendo.2022.1017177"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.1017177","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,7]]},"article-number":"1017177"}}